Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ANS03 |
Synonyms | |
Therapy Description |
Limited information is currently available on ANS03, a putative ROS1 and NTRK inhibitor (Dec 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ANS03 | ANS-03|ANS 03 | ROS1 Inhibitor 22 Trk Receptor Inhibitor (Pan) 33 | Limited information is currently available on ANS03, a putative ROS1 and NTRK inhibitor (Dec 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06716138 | Phase I | ANS03 | A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors | Not yet recruiting | USA | 1 |